---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-023732"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2025-06-26T23:59:59+00:00"
generated_at: "2026-05-18T17:31:32.249248+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Opus Genetics VEGA-3 Phase 3 trial meets primary endpoint for presbyopia treatment

## Summary
- 27.2% of patients on drug achieved ≥15-letter DCNVA gain vs 11.5% placebo (p<0.0001) at 12h post-dose on Day 8.
- Safety profile consistent with prior trials; no treatment-related serious adverse events reported.
- No evidence of tachyphylaxis over the 6-week study period.
- NDA submission to FDA planned for the second half of 2025.
- Cash on hand expected to fund operations into H2 2026.

## SEC filing metadata
- accession: 0001140361-25-023732
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2025-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036125023732/0001140361-25-023732-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036125023732/ef20051231_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-023732
- JSON: https://secwatch.observer/filing/0001140361-25-023732.json
- Plain text: https://secwatch.observer/filing/0001140361-25-023732.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.